DCGI gives Nod for Restricted Emergency Use to Itolizumab
Itolizumab (rDNA origin) has now been granted Restricted Emergency Use authorisation by the Drugs Controller General of India (DCGI) based on clinical trials data. It is a monoclonal antibody which was already approved for severe chronic plaque psoriasis. Daily Current Affairs Quiz 2020 Key-Points M/s Biocon has been manufacturing and marketing this drug for the […]
DCGI gives Nod for Restricted Emergency Use to Itolizumab Read More »










